Lyell Immunopharma, Inc.

Historical 13F Holders

Symbol
LYEL
CUSIP
55083R104
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 55083R104 since 12/18/2024, largest first.

Filer % of Class Filed
ARCH Venture Fund IX, L.P. 13G/A
13.1% 2/14/2025
Event 12/31/2024
Foresite Capital Fund IV, L.P. 13G/A
9.2% 5/15/2025
Event 3/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
Explore Investments LLC/DE 13G
Amended under CUSIP 55083R203 on 5/8/2026
5.4% 8/19/2025
Event 7/25/2025
BlackRock, Inc. 13G/A 4.5% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q2 1 692 k $9.72M
2026 Q1 1 692 k $13.9M
2025 Q4 1 692 k $21.3M
2025 Q3 2 650 k $10.6M
2025 Q2 6 2.44 M $21.6M
2025 Q1 113 152 M $81.8M
2024 Q4 106 150 M $95.9M
2024 Q3 118 128 M $176M
2024 Q2 121 134 M $194M
2024 Q1 128 133 M $297M
2023 Q4 121 131 M $255M
2023 Q3 107 123 M $180M
2023 Q2 100 122 M $389M
2023 Q1 100 118 M $278M
2022 Q4 96 117 M $405M
2022 Q3 94 112 M $823M
2022 Q2 77 106 M $689M
2022 Q1 81 99.5 M $503M
2021 Q4 78 85.5 M $662M
2021 Q3 63 82.5 M $1.22B
2021 Q2 53 79.7 M $1.29B